Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (26)

2024

  1. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

  2. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open

  3. Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age

    Journal of Infectious Diseases, Vol. 230, Núm. 2, pp. e333-e341

  4. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

    Nature communications, Vol. 15, Núm. 1, pp. 3083

2023

  1. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

    The Lancet Infectious Diseases, Vol. 23, Núm. 7, pp. 856-866

  2. Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design – A population-based study

    Revista Portuguesa de Cardiologia, Vol. 42, Núm. 12, pp. 985-995

2022

  1. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  2. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  3. Multi-omics signatures of the human early life exposome

    Nature Communications, Vol. 13, Núm. 1

  4. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  5. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

    Journal of Clinical Epidemiology, Vol. 147, pp. 11-20

2021

  1. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

    Nature Communications, Vol. 12, Núm. 1

  2. Global and regional burden of hospital admissions for pneumonia in older adults: A systematic review and meta-analysis

    Journal of Infectious Diseases, Vol. 222, pp. S570-S576

  3. Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections

    Journal of Infectious Diseases, Vol. 222, pp. S584-S591

  4. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 3, pp. 260-274

  5. Publisher Correction: Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus (Nature Communications, (2021), 12, 1, (5125), 10.1038/s41467-021-25265-4)

    Nature Communications

  6. Variability of multi-omics profiles in a population-based child cohort

    BMC Medicine, Vol. 19, Núm. 1

2020

  1. Global molecular diversity of RSV - The "iNFORM RSV" study

    BMC Infectious Diseases, Vol. 20, Núm. 1

  2. In utero and childhood exposure to tobacco smoke and multi-layer molecular signatures in children

    BMC Medicine, Vol. 18, Núm. 1

  3. Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1034-1051